COVID-19 trials registries data warehouse

https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=14661

Hussein AbdurRazzaq

haderazz05@ymail.com

2021-02-05

Not recruiting

RCT

Randomized

Parallel

Open label

multi-center

Treatment

(1) Provide written informed consent prior to initiation of any study procedures (2) Understand and agree to comply with planned study procedures (3) Agree to the collection of oropharyngeal swabs and venous blood per protocol (4) Be male or non-pregnant female adult =18 years of age at time of enrolment (5) Have laboratory-confirmed SARS-CoV-2 infection as determined by RT-PCR in any specimen no more than 72 hours prior to randomisation.

1. American Society of Anaesthesiologists (ASA) class 3 and above. 2. Stage 4 severe chronic kidney disease or requiring dialysis (eGFR < 30) 3. Pregnant or breast feeding. 4. Anticipated transfer to another facility which is not a study site within 72 hours. 5. Participants with known haematological diseases (G6PD deficiency) 6. Participants with chronic liver and kidney disease and reaching end-stage. 7. Participants with arrhythmia and chronic heart disease. 8. Participants known to have retinal disease or hearing loss. 9. Participants known to have a mental illness. 10. Skin disorders (including rash, dermatitis, psoriasis). 11. Allergy to Ivermectin or its analogues.

2

LAGOS STATE MINISTRY OF HEALTH

18

85

Nigeria

No restriction on type of patients

0: No restriction on type of patients

240

Mortality

| Declared number of arm (2.0) differs from found arms (3.0)

Phase 3

[{"arm_notes": "", "treatment_id": 693, "treatment_name": "Ivermectin", "treatment_type": "Antiparasitics", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]